In Q1 FY2026 (ended March 31, 2026), Novavax reported revenue of $139.5 million, a 79.1% decline year-over-year. Net loss was $9.5 million, compared to net income in the prior year. Operating loss was $15.4 million, and diluted EPS was -$0.06. Cash stood at $228.4 million, with negative equity of $144.8 million and long-term debt of $291.0 million.
•Revenue fell 79.1% YoY to $139.5 million.
•Net loss of $9.5 million vs. net income in prior year.
•Operating loss of $15.4 million, down 103.0% YoY.
•Cash of $228.4 million, negative equity of $144.8 million, long-term debt of $291.0 million.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Novavax, Inc., a biotechnology company provides the discovery, development, and commercialization of vaccines to prevent serious infectious diseases globally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. Incorporated in 1987, the company is headquartered in Gaithersburg, Maryland.
Novavax, Inc. is a biotechnology company focused on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases globally. The company's main products include Nuvaxovid, a COVID-19 vaccine, and the R21 Matrix-M adjuvant malaria vaccine. Novavax also has license and collaboration agreements with major pharmaceutical companies such as Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited to develop, manufacture, and commercialize its COVID-19 vaccine. Founded in 1987, Novavax is headquartered in Gaithersburg, Maryland, and operates in the United States.
Where is Novavax (NVAX) listed and in which currency?
Novavax, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol NVAX. The stock trades in U.S. dollars (USD), which is the official currency of the United States. As a company headquartered in the U.S. and listed on a major American exchange, its financial reporting and stock price are denominated in USD. Investors trading NVAX shares typically use U.S. dollars, and the stock is subject to the trading rules and regulations of the Nasdaq exchange.
What sector and industry does Novavax (NVAX) belong to?
Novavax operates in the Healthcare sector and specifically within the Biotechnology industry. As a biotechnology company, it focuses on using biological processes and organisms to develop vaccines and other medical products. The biotechnology industry is known for its research-intensive nature, requiring significant investment in R&D to bring new therapies to market. Novavax's work in developing vaccines for infectious diseases like COVID-19 and malaria places it at the forefront of public health innovation. The company's classification as a healthcare biotechnology firm reflects its mission to prevent serious infectious diseases through advanced vaccine technology.
Where is Novavax (NVAX) headquartered and what markets does it serve?
Novavax, Inc. is headquartered in Gaithersburg, Maryland, United States. The company serves global markets, as indicated by its description of providing vaccines to prevent serious infectious diseases globally. Its COVID-19 vaccine, Nuvaxovid, has been distributed internationally, and its collaboration with partners like Serum Life Sciences Limited (based in India) and Takeda (Japan) supports manufacturing and commercialization in various regions. Additionally, the R21 Matrix-M malaria vaccine targets regions where malaria is endemic, primarily in Africa and other tropical areas. While Novavax is a U.S.-based company, its operations and impact extend worldwide through partnerships and product distribution.
How does Novavax (NVAX) generate revenue?
Novavax generates revenue primarily through the commercialization of its vaccines, including Nuvaxovid (COVID-19 vaccine) and the R21 Matrix-M malaria vaccine. The company also earns revenue from license and collaboration agreements with partners such as Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited. These agreements involve upfront payments, milestone payments, and royalties on future sales of vaccines developed or commercialized under the partnerships. Additionally, Novavax may receive funding from government contracts or grants for vaccine development and supply. As a biotechnology company, its revenue is closely tied to the success of its vaccine candidates and the scale of global vaccination efforts.